The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How does sequencing of FLT3 inhibitor therapy affect outcome?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Jorge Cortes, Augusta University, Augusta, US. We asked, How does sequencing of FLT3 inhibitor therapy affect outcome?

How does sequencing of FLT3 inhibitor therapy affect outcome?

Despite having a range of FLT3 inhibitors with different indications, and with some already approved in the US, patients receiving these inhibitors develop resistance and have to switch to an alternative FLT3 inhibitor. In this video, Cortes outlines the studies from ASH 2020 addressing the likelihood of responsiveness to subsequent FLT3 inhibitors.

 

Share: